



Ridgeback Biotherapeutics and Merck Announce Preliminary  
Findings from a Phase 2a Trial of Investigational COVID-19  
Therapeutic Molnupiravir - Merck.com

<https://www.merck.com/news/ridgeback-biotherapeutics-and-merck-announce-preliminary-findings-from-a-phase-2a-trial-of-investigational-covid-19-therapeutic-molnupiravir/>